Tirzepatide Pharma (MayMag Biologics) — 506e FDA Registered Pharma for sterile Biologics and Generic medicines under short list category
Resolve critical shortages. We compound currently in shortage drugs (506E): commercial-scale GLP-1 biologics, epinephrine pens, and RA medications.
Discover MayMag Biologics, the premier manufacturer of sterile glaucoma treatments.
Sterile Glaucoma Medications
Insulin Products — Global Distribution
GLP-1 Sterile Injectables
GMP Certified Facility
FDA · cGMP · 506E Registered
What We Do
506e Industrial Contract Manufacturing Pharma
Large-scale sterile injectable biologics manufacturing under FDA 506e outsourcing facility designation.
Recovery & Wellness
High-purity compounded peptides and wellness injectables for clinical and institutional use.
cGMP-Customized GLP1-Peptides
Glutathione Vials Superantioxidant
Natural Female Balance Peptide
High Purity Pharma-Vitamin
What sets us apart from other 506e pharmas
We are local, based in the United States, with drug quality controlled and monitored.
We have the scale, facility redundancy, and device supply chain to meet 100% of your market demand without a single day of backorder, with multiple FDA-compliant, GMP-certified facilities for both the active drug substance and the 'fill-finish' final step.
We understand how to handle the stability requirements of large batches, from formulation through transportation, without risking product degradation.
MayMag maintains device continuity assurance with in-house 510k auto device pen manufacturing, clean FDA Form 483 records, and zero warning letters.
FDA · cGMP · 506E
506E Industrial Sterile Facility — Secure your supply chain with our FDA-registered outsourcing facility. We specialize in compounding FDA section 506e short-listed drugs to cGMP standards.
Reliable manufacturing for FDA short-listed drugs
Our cGMP facility mitigates drug shortage list (506E) gaps with scaled sterile fill-finish operations. We're your trusted Partner for injectable Biologics.
Leading 506e outsourcing facility mitigating FDA drug shortages. Scale production for GLP-1 biologics, epinephrine auto-pens, & RA injectables.
Contact us
The GLP-1 Paradox
High demand meets real-world barriers: cost, access, and long-term sustainability. Our biomimicry approach offers an oral metabolic stack designed as a GLP-1 alternative.